Literature DB >> 22315262

Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Samantha MacLean1, Sohail Mulla2, Elie A Akl3, Milosz Jankowski4, Per Olav Vandvik5, Shanil Ebrahim2, Shelley McLeod6, Neera Bhatnagar7, Gordon H Guyatt2.   

Abstract

BACKGROUND: Development of clinical practice guidelines involves making trade-offs between desirable and undesirable consequences of alternative management strategies. Although the relative value of health states to patients should provide the basis for these trade-offs, few guidelines have systematically summarized the relevant evidence. We conducted a systematic review relating to values and preferences of patients considering antithrombotic therapy.
METHODS: We included studies examining patient preferences for alternative approaches to antithrombotic prophylaxis and studies that examined, in the context of antithrombotic prophylaxis or treatment, how patients value alternative health states and experiences with treatment. We conducted a systematic search and compiled structured summaries of the results. Steps in the process that involved judgment were conducted in duplicate.
RESULTS: We identified 48 eligible studies. Sixteen dealt with atrial fibrillation, five with VTE, four with stroke or myocardial infarction prophylaxis, six with thrombolysis in acute stroke or myocardial infarction, and 17 with burden of antithrombotic treatment.
CONCLUSION: Patient values and preferences regarding thromboprophylaxis treatment appear to be highly variable. Participant responses may depend on their prior experience with the treatments or health outcomes considered as well as on the methods used for preference elicitation. It should be standard for clinical practice guidelines to conduct systematic reviews of patient values and preferences in the specific content area.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22315262      PMCID: PMC3278050          DOI: 10.1378/chest.11-2290

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  53 in total

1.  Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.

Authors:  P J Devereaux; D R Anderson; M J Gardner; W Putnam; G J Flowerdew; B F Brownell; S Nagpal; J L Cox
Journal:  BMJ       Date:  2001-11-24

2.  Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study.

Authors:  Simon I R Noble; I G Finlay
Journal:  Palliat Med       Date:  2005-04       Impact factor: 4.762

3.  Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study.

Authors:  S I R Noble; A Nelson; C Turner; I G Finlay
Journal:  BMJ       Date:  2006-02-03

4.  Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation.

Authors:  A Howitt; D Armstrong
Journal:  BMJ       Date:  1999-05-15

5.  Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences.

Authors:  Mirjam Locadia; Patrick M M Bossuyt; Peep F M Stalmeier; Mirjam A G Sprangers; Carlo J J van Dongen; Saskia Middeldorp; Ivan Bank; Jan van der Meer; Karly Hamulyák; Martin H Prins
Journal:  Thromb Haemost       Date:  2004-12       Impact factor: 5.249

6.  A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial.

Authors:  M Man-Son-Hing; A Laupacis; A M O'Connor; J Biggs; E Drake; E Yetisir; R G Hart
Journal:  JAMA       Date:  1999-08-25       Impact factor: 56.272

7.  Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation.

Authors:  R Thomson; D Parkin; M Eccles; M Sudlow; A Robinson
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

8.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

9.  A patient decision aid to support shared decision-making on anti-thrombotic treatment of patients with atrial fibrillation: randomised controlled trial.

Authors:  Richard G Thomson; Martin P Eccles; I Nick Steen; Jane Greenaway; Lynne Stobbart; Madeleine J Murtagh; Carl R May
Journal:  Qual Saf Health Care       Date:  2007-06

10.  A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation.

Authors:  Greg Samsa; David B Matchar; Rowena J Dolor; Ingela Wiklund; Ewa Hedner; Gail Wygant; Ole Hauch; Cheryl Beadle Marple; Roger Edwards
Journal:  Health Qual Life Outcomes       Date:  2004-05-06       Impact factor: 3.186

View more
  87 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Introduction to the ninth edition: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; Elie A Akl; Mark Crowther; Holger J Schünemann; David D Gutterman; Sandra Zelman Lewis
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Roman Jaeschke; Scott M Stevens; Steven Goodacre; Philip S Wells; Matthew D Stevenson; Clive Kearon; Holger J Schunemann; Mark Crowther; Stephen G Pauker; Regina Makdissi; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John J You; Daniel E Singer; Patricia A Howard; Deirdre A Lane; Mark H Eckman; Margaret C Fang; Elaine M Hylek; Sam Schulman; Alan S Go; Michael Hughes; Frederick A Spencer; Warren J Manning; Jonathan L Halperin; Gregory Y H Lip
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

6.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 7.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

8.  Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Pablo Alonso-Coello; Sergi Bellmunt; Catherine McGorrian; Sonia S Anand; Randolph Guzman; Michael H Criqui; Elie A Akl; Per Olav Vandvik; Maarten G Lansberg; Gordon H Guyatt; Frederick A Spencer
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

9.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

10.  Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis.

Authors:  T Enden; S Resch; C White; H S Wik; N E Kløw; P M Sandset
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.